Abstract
In the commonly accepted paradigm for control of the mammalian cell cycle, sequential cyclin-dependent kinase (CDK) and cyclin activities drive the orderly transition from G1 to S phase. However, recent studies using different technological approaches and examining a broad range of cancer cell types are challenging this established paradigm. An alternative model is evolving in which cell cycles utilize different drivers and take different trajectories through the G1/S transition. We are discovering that cancer cells in particular can adapt their drivers and trajectories, which has important implications for antiproliferative therapies. These studies have helped to refine an understanding of how CDK inhibition impinges on proliferation and have significance for understanding fundamental features of cell biology and cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 636-645 |
Number of pages | 10 |
Journal | Trends in Cell Biology |
Volume | 34 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2024 |
Externally published | Yes |
Keywords
- CDK2 inhibitors
- CDK4/6 inhibitors
- CDKN2A-p16
- cyclin D1
- cyclin E
- cyclin-dependent kinase
- retinoblastoma pathway
ASJC Scopus subject areas
- Cell Biology